In view of possible equivalent efficacy of low dose abiraterone with food, has anyone had clinical experience offering low dose abiraterone to spare patients from financial toxicity of abiraterone?
Answer from: Medical Oncologist at Academic Institution
The Szmulewitz study is a well done and robust pharmacokinetic study of low dose abiraterone with food. There is a well written commentary from Glenn Liu in the same issue of JCO.While the study does show pharmacokinetic equivalence, it is difficult to extrapolate comfortably to clinical equivalence...
Comments
Medical Oncologist at University of Colorado Denver The financials are not insignificant, particularly...
Medical Oncologist at Duke University School of Medicine Given the similar PSA declines, PSA PFS, and PK pa...
The financials are not insignificant, particularly...
Given the similar PSA declines, PSA PFS, and PK pa...